The Nebraska Medical Center
- Type
- Teaching hospital
- Where
- Omaha, NE
- Medicare CCN
- 280013
- Received
- $1,334,700 in 137 records, 2024 ($424,642 general, $910,057 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Business registration: THE NEBRASKA MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Plan sponsor: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: NEBRASKA MEDICAL CENTER, THE Fuzzy (name and state)
- Federal award recipient: NEBRASKA MEDICAL CENTER, THE Fuzzy (name and state)
- Nonprofit: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: The Nebraska Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 93 | $424,642 |
| 2024 | Research payment | 44 | $910,057 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Genmab U.S., Inc. | 12 | $464,301 | 2024 |
| INSTRUMENTATION LABORATORY COMPANY | 4 | $160,387 | 2024 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $141,149 | 2024 |
| XVIVO Perfusion Inc. | 1 | $130,304 | 2024 |
| Genentech USA, Inc. | 1 | $100,000 | 2024 |
| OCCLUTECH US LLC | 1 | $76,262 | 2024 |
| National Marrow Donor Program | 4 | $72,430 | 2024 |
| Zimmer Biomet Holdings, Inc. | 4 | $31,280 | 2024 |
| AngioDynamics, Inc. | 1 | $30,000 | 2024 |
| Medical Device Business Services, Inc. | 9 | $25,000 | 2024 |
| AtriCure, Inc. | 2 | $24,148 | 2024 |
| Insulet Corporation | 20 | $23,325 | 2024 |
| Olympus America Inc. | 2 | $15,677 | 2024 |
| Tandem Diabetes Care, Inc. | 26 | $14,700 | 2024 |
| Alnylam Pharmaceuticals Inc. | 7 | $10,250 | 2024 |
| Incyte Corporation | 3 | $4,909 | 2024 |
| Stryker Corporation | 3 | $3,108 | 2024 |
| Teleflex LLC | 1 | $2,788 | 2024 |
| Impulse Dynamics (USA) Inc. | 1 | $2,500 | 2024 |
| Becton, Dickinson and Company | 3 | $564 | 2024 |
| W. L. Gore & Associates, Inc. | 1 | $504 | 2024 |
| Mallinckrodt Hospital Products Inc. | 1 | $391 | 2024 |
| Monteris Medical Corporation | 1 | $264 | 2024 |
| ConvaTec Inc. | 1 | $251 | 2024 |
| Siemens Medical Solutions USA, Inc. | 1 | $203 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 44 | $910,057 |
| Space rental or facility fees (teaching hospital only) | 22 | $174,689 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 57 | $120,705 |
| Grant | 2 | $76,514 |
| Long term medical supply or device loan | 4 | $33,333 |
| Debt forgiveness | 7 | $19,381 |
| Education | 1 | $20 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | OCCLUTECH US LLC | $76,262 | Grant (6 payments) | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | AngioDynamics, Inc. | $30,000 | Long term medical supply or device loan | In-kind items and services | Auryon Laser System 100-120 Vac Device, ET | 2024 | |
| 2024-12-31 | Teleflex LLC | $2,788 | Long term medical supply or device loan | In-kind items and services | WECK Device, SURGICAL | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,569 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $1,503 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Becton, Dickinson and Company | $510 | Long term medical supply or device loan | In-kind items and services | 2024 | ||
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $203 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-12-31 | Stryker Corporation | $35 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Becton, Dickinson and Company | $34 | Long term medical supply or device loan | In-kind items and services | 2024 | ||
| 2024-12-27 | INSTRUMENTATION LABORATORY COMPANY | $48,199 | Research payment | Cash or cash equivalent | HIT START UP 2022 | 2024 | |
| 2024-12-27 | INSTRUMENTATION LABORATORY COMPANY | $23,370 | Research payment | Cash or cash equivalent | L0000024418 FRESH VS FROZEN | 2024 | |
| 2024-12-27 | Zimmer Biomet Holdings, Inc. | $5,484 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RIBFIX BLU ADVANTAGE Device, CMF & Thoracic | 2024 | |
| 2024-12-20 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-18 | Medical Device Business Services, Inc. | $3,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-12-18 | Tandem Diabetes Care, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-11 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-10 | INSTRUMENTATION LABORATORY COMPANY | $77,901 | Research payment | Cash or cash equivalent | L0000024418 FRESH VS FROZEN | 2024 | |
| 2024-12-06 | Medical Device Business Services, Inc. | $3,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-12-06 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | Alnylam Pharmaceuticals Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-04 | Tandem Diabetes Care, Inc. | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-02 | Medical Device Business Services, Inc. | $3,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-12-02 | Medical Device Business Services, Inc. | $2,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-26 | Medical Device Business Services, Inc. | $3,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-26 | Medical Device Business Services, Inc. | $2,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-26 | Medical Device Business Services, Inc. | $2,400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-26 | Medical Device Business Services, Inc. | $1,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-25 | Medical Device Business Services, Inc. | $3,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CARTO 3 Device, Cardiology | 2024 | |
| 2024-11-20 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | Tandem Diabetes Care, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-20 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-20 | Mallinckrodt Hospital Products Inc. | $391 | Debt forgiveness | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | 2024 | |
| 2024-11-07 | Alnylam Pharmaceuticals Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-11-06 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-05 | Takeda Pharmaceuticals U.S.A., Inc. | $12,984 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-11-05 | Takeda Pharmaceuticals U.S.A., Inc. | $4,328 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-11-04 | Incyte Corporation | $2,059 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2024 | |
| 2024-10-30 | Insulet Corporation | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-25 | National Marrow Donor Program | $18,255 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-23 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-16 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-10 | Alnylam Pharmaceuticals Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-10 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $4,328 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-10-02 | AtriCure, Inc. | $10,862 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | LEFT ATRIAL APPENDAGE EXCLUSION FOR PROPHYLACTIC STROKE REDUCTION TRIAL | 2024 |
| 2024-10-02 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-27 | Becton, Dickinson and Company | $20 | Education | In-kind items and services | 2024 | ||
| 2024-09-23 | Impulse Dynamics (USA) Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Optimizer Device, Cardiovascular Device | 2024 | |
| 2024-09-20 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-18 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-13 | Zimmer Biomet Holdings, Inc. | $1,332 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RIBFIX BLU ADVANTAGE Device, CMF & Thoracic | 2024 | |
| 2024-09-12 | Genmab U.S., Inc. | $5,880 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-09-11 | Insulet Corporation | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $15,534 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-09 | Takeda Pharmaceuticals U.S.A., Inc. | $7,575 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-09-05 | Genmab U.S., Inc. | $18,319 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-09-05 | Alnylam Pharmaceuticals Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-09-05 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-28 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-22 | Genmab U.S., Inc. | $16,670 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-08-22 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-08-21 | Genentech USA, Inc. | $100,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Ocrevus Biological, Immunology | 2024 | |
| 2024-08-21 | Tandem Diabetes Care, Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-18 | Monteris Medical Corporation | $264 | Research payment | In-kind items and services | NeuroBlate Device, NeuroBlate | LITT | 2024 |
| 2024-08-15 | Zimmer Biomet Holdings, Inc. | $5,604 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Juggerknotless Soft Anchor Device, Sports Medicine | 2024 | |
| 2024-08-15 | ConvaTec Inc. | $251 | Grant | In-kind items and services | NATURABILAM W/INVISICTFPOKIT70MM Device, OSTOMY CARE | 2024 | |
| 2024-08-13 | Olympus America Inc. | $9,851 | Debt forgiveness | In-kind items and services | URETERO-RENO VIDEOSCOPE Device, Urology Gynecology | 2024 | |
| 2024-08-13 | Olympus America Inc. | $5,826 | Debt forgiveness | In-kind items and services | EVIS EXERA III BRONCHOVIDEOSCOPE Device, Gastroenterology | 2024 | |
| 2024-08-12 | INSTRUMENTATION LABORATORY COMPANY | $10,916 | Research payment | In-kind items and services | 2024 | ||
| 2024-08-08 | Genmab U.S., Inc. | $4,848 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-08-08 | Alnylam Pharmaceuticals Inc. | $1,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-07 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-02 | Genmab U.S., Inc. | $39,476 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-08-01 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-26 | National Marrow Donor Program | $25,090 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-26 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-07-25 | Genmab U.S., Inc. | $24,768 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-07-24 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-05 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
| 2024-07-05 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
| 2024-07-05 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
| 2024-07-03 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-07-02 | AtriCure, Inc. | $13,286 | Research payment | Cash or cash equivalent | ATRICLIP LAA EXCLUSION SYSTEM Device, CARDIOVASCULAR | LEFT ATRIAL APPENDAGE EXCLUSION FOR PROPHYLACTIC STROKE REDUCTION TRIAL | 2024 |
| 2024-07-02 | Alnylam Pharmaceuticals Inc. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-06-26 | Genmab U.S., Inc. | $10,147 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-06-26 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-06-06 | Genmab U.S., Inc. | $83,112 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-06-06 | Alnylam Pharmaceuticals Inc. | $4,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-06-05 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-05-30 | Genmab U.S., Inc. | $19,856 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-05-30 | Genmab U.S., Inc. | $6,530 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-05-30 | Genmab U.S., Inc. | $5,273 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-05-29 | Takeda Pharmaceuticals U.S.A., Inc. | $21,640 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-05-22 | Insulet Corporation | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-16 | XVIVO Perfusion Inc. | $130,304 | Research payment | Cash or cash equivalent | XVIVO Heartbox and its components Device, Transplant Perfusion | PRESERVE Heart Study | 2024 |
| 2024-05-16 | Insulet Corporation | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-26 | National Marrow Donor Program | $12,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-25 | Zimmer Biomet Holdings, Inc. | $18,858 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Persona Device, Knees | 2024 | |
| 2024-04-24 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-17 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-04-10 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-02 | Insulet Corporation | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-29 | W. L. Gore & Associates, Inc. | $504 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GREAT Global Registry for Endovascular Aortic Treatment | 2024 |
| 2024-03-27 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-26 | Takeda Pharmaceuticals U.S.A., Inc. | $1,315 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2024 | |
| 2024-03-25 | Takeda Pharmaceuticals U.S.A., Inc. | $12,984 | Research payment | In-kind items and services | NINLARO Drug, ONCOLOGY | X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT | 2024 |
| 2024-03-22 | Takeda Pharmaceuticals U.S.A., Inc. | $1,716 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | HUNTER OUTCOME SURVEY: A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL REGISTRY OF PATIENTS WITH HUNTER SYNDROME (MUCOP | 2024 |
| 2024-03-22 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-20 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-03-07 | Genmab U.S., Inc. | $229,415 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. | 2024 |
| 2024-03-06 | Takeda Pharmaceuticals U.S.A., Inc. | $750 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | HUNTER OUTCOME SURVEY: A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL REGISTRY OF PATIENTS WITH HUNTER SYNDROME (MUCOP | 2024 |
| 2024-03-06 | Takeda Pharmaceuticals U.S.A., Inc. | $250 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | HUNTER OUTCOME SURVEY: A GLOBAL, MULTI-CENTER, LONG-TERM, OBSERVATIONAL REGISTRY OF PATIENTS WITH HUNTER SYNDROME (MUCOP | 2024 |
| 2024-03-05 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-04 | Incyte Corporation | $850 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MONJUVI Drug, Oncology | 2024 | |
| 2024-02-28 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-22 | Insulet Corporation | $2,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-02-21 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-08 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-05 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-01-31 | Tandem Diabetes Care, Inc. | $1,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-24 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-12 | National Marrow Donor Program | $16,565 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-12 | Incyte Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2024 | |
| 2024-01-10 | Takeda Pharmaceuticals U.S.A., Inc. | $3,780 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFAS | 2024 |
| 2024-01-10 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-03 | Tandem Diabetes Care, Inc. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-01-03 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
| 2024-01-03 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
| 2024-01-03 | Takeda Pharmaceuticals U.S.A., Inc. | $848 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Omaha, NE, county Douglas County, NE, state Nebraska; placed by its city name.
| Measure | Place (city or town) Omaha, NE | County Douglas County, NE | State Nebraska |
|---|---|---|---|
| Population B01003 | 488,837 | 590,736 | 1,978,707 |
| Population, 2020 census P1 | 486,051 | 584,526 | 1,961,504 |
| Median age B01002 | 35.3 | 35.6 | 37.2 |
| Under 18 B01001 | 24.2% | 25.3% | 24.5% |
| 65 and over B01001 | 14.5% | 14.1% | 16.7% |
| Households B11001 | 201,698 | 238,430 | 797,847 |
| Foreign born B05002 | 11.3% | 10.6% | 8.0% |
| Median household income B19013 | $73,201 | $80,391 | $76,475 |
| Median family income B19113 | $99,432 | $108,805 | $99,751 |
| Per capita income B19301 | $43,638 | $46,334 | $41,751 |
| Poverty rate B17001 | 13.5% | 11.8% | 10.6% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.0% |
| Civilian labor force B23025 | 264,681 | 320,024 | 1,056,746 |
| Mean commute (minutes) B08013 | 19.6 | 20.0 | 19.2 |
| Bachelor's degree or higher B15003 | 40.1% | 42.1% | 34.6% |
| Housing units B25001 | 213,023 | 251,553 | 863,444 |
| Owner-occupied B25003 | 57.4% | 61.5% | 66.5% |
| Renters B25003 | 42.6% | 38.5% | 33.5% |
| Median home value B25077 | $245,500 | $266,100 | $238,600 |
| Median gross rent B25064 | $1,187 | $1,201 | $1,072 |
| White, not Hispanic B03002 | 63.4% | 65.8% | 75.3% |
| Black B03002 | 11.4% | 10.2% | 4.6% |
| Hispanic or Latino B03002 | 16.2% | 14.5% | 12.7% |
| Asian B03002 | 4.0% | 4.4% | 2.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Omaha, NE.
Comments